Prolonged postoperative venous thrombo-embolism prophylaxis is cost-effective in advanced ovarian cancer patients
- 1 December 2012
- journal article
- Published by Elsevier in Gynecologic Oncology
- Vol. 127 (3), 631-637
- https://doi.org/10.1016/j.ygyno.2012.08.032
Abstract
No abstract availableKeywords
This publication has 32 references indexed in Scilit:
- Consolidation paclitaxel is more cost-effective than bevacizumab following upfront treatment of advanced epithelial ovarian cancerGynecologic Oncology, 2011
- Cost comparison of strategies for the management of venous thromboembolic event risk following laparotomy for ovarian cancerGynecologic Oncology, 2011
- Incidence and timing of venous thromboembolism after surgery for gynecological cancerGynecologic Oncology, 2011
- A Protocol of Dual Prophylaxis for Venous Thromboembolism Prevention in Gynecologic Cancer PatientsObstetrics & Gynecology, 2008
- Prevention of Venous ThromboembolismChest, 2008
- Incidence of Venous Thromboembolism in Patients With Ovarian Cancer Undergoing Platinum/Paclitaxel–Containing First-Line Chemotherapy: An Exploratory Analysis by the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study GroupJournal of Clinical Oncology, 2008
- Cancer and venous thromboembolism: prevention, treatment and survivalJournal of Thrombosis and Thrombolysis, 2007
- Long-term Low-Molecular-Weight Heparin versus Usual Care in Proximal-Vein Thrombosis Patients with CancerThe American Journal of Medicine, 2006
- Outcomes and Cost of Deep Venous Thrombosis Among Patients With CancerArchives of Internal Medicine, 2004
- Low-Molecular-Weight Heparin versus a Coumarin for the Prevention of Recurrent Venous Thromboembolism in Patients with CancerNew England Journal of Medicine, 2003